Kornimate/medical-research-clean huggingface dataset:
comparison of aspheric toric & non-toric aphakic intraocular lenses

Conditions: Aphakia; Cataract

Summary: the purpose of this multi-center clinical trial is to determine the safety and efficacy of the hso toric iols for the correction of aphakia and reduction of pre-existing refractive astigmatism.


Eligibility criteria:
inclusion criteria: * have been diagnosed with cataract for which phacoemulsification extraction and posterior chamber iol implantation is indicated * have at least one eye that meets the ranges of pre-operative corneal cylinder as specified by this study's guidelines, i.e. corneal cylinder of at least 1.0 d (after accounting for changes in corneal cylinder due to the incision) * have potential best corrected visual acuity of 20/30 or better after implantation of a study lens * have clear intraocular media other than cataract * have preoperative best corrected visual acuity equal to 20/40 or worse, with or without a glare source exclusion criteria: * have atonic pupils or physiologically small pupils in either eye (unable to dilate to at least 4 mm) * have irregular astigmatism in the operative eye, or refractive cylinder resulting only from lenticular astigmatism in the operative eye * have corneal pathology potentially affecting corneal topography, or other corneal abnormalities that do or are expected to reduce best corrected visual acuity in the operative eye during the study period * have undergone previous refractive corneal surgery in the operative eye * have been diagnosed with any degenerative retinal disorders (e.g. soft drusen, macular degeneration or other progressive retinal disorders) in the operative eye that are predicted to cause future visual acuity losses to a level of 20/30 or worse during the postoperative follow-up time requirements of this study eligibility criteria not complete. contact hoya surgical optics, inc. for more information.

Keywords: intraocular lens iol cataract refractive astigmatism aspheric toric hoya surgical optics visual acuity
cryopreserved human umbilical cord as a meningeal patch in fetoscopic spina bifida repair

Conditions: Spina Bifida; Fetus; Myelomeningocele; Myeloschisis

Summary: the objective is to test the efficacy of a laparotomy-assisted fetoscopic surgical approach to cover spina bifida spinal cord developmental defects using cryopreserved human umbilical cords (neox cord 1k®) as a meningeal and skin patch.


Eligibility criteria:
inclusion criteria: maternal inclusion criteria: 1. singleton pregnancy 2. gestational age at screening is 19 to 25 5/7 weeks and gestational age at surgery is 22 to 25 6/7 weeks 3. maternal age: 18 years and older 4. body mass index ≤45 kg/m2 (pre-pregnancy) 5. no preterm birth risk factors (short cervix \<20 mm or a history of previous preterm delivery) 6. no previous uterine incision in the active uterine segment 7. willing to undergo an open fetal repair if the fetoscopic approach is unsuccessful fetal inclusion criteria: 1. spina bifida defect between t1 to s1 vertebral levels 2. chiari ii malformation 3. no evidence of kyphosis (curved spine) 4. no major life-threatening fetal anomaly unrelated to spina bifida 5. normal karyotype, or a normal chromosomal microarray analysis (cma), or a cma with variants of unknown significance \[fluorescence in situ hybridization (fish) acceptable if ≥ 24 weeks\]. exclusion criteria: maternal exclusion criteria: 1. non-resident of the united states 2. multifetal pregnancy 3. poorly controlled insulin-dependent pregestational diabetes 4. poorly controlled a2 diabetes mellitus (a2dm) insulin-dependent diabetes 5. current or planned cerclage or documented history of an incompetent cervix 6. placenta previa or placental abruption 7. short cervix of \< 20 mm 8. obesity as defined by a body mass index of \> 45 kg/m2 9. previous spontaneous singleton delivery prior to 37 weeks 10. maternal-fetal rh isoimmunization, kell sensitization, or a history of neonatal alloimmune thrombocytopenia 11. hiv or hepatitis-b positive status 12. known hepatitis-c positivity 13. uterine anomaly such as large or multiple fibroids or a mullerian duct abnormality that is diagnosed via imaging prior to surgery, which that are unavoidable during surgery 14. other medical conditions which are contraindication to surgery or general anesthesia 15. patient does not have a support person 16. inability to comply with the travel and follow-up requirements of the trial 17. patient does not meet psychosocial standardized assessment criteria 18. participation in this or another intervention study that influences maternal and fetal morbidity and mortality 19. maternal hypertension 20. zika virus positivity 21. allergy/history of drug reaction to amphotericin b fetal exclusion criteria: 1. major fetal anomaly not related to spina bifida 2. kyphosis in the fetus of 30 degrees or more 3. ventriculomegaly greater than 15 mm and no movements noted at hip and knee joints

Keywords: fetoscopic fetal intervention human umbilical cord neox cord 1k
study of lactobacillus in adjuvant treatment of rvvc

Conditions: Recurrent Vulvovaginal Candidiasis

Summary: we are trying to determine if clotrimazole vaginal tablets with oral lactobacillus is better than clotrimazole vaginal tablets in preventing the recurrence of vulvovaginalcandidiasis

vulvovaginal candidiasis is common disease in women. its refractory and high recurrence rate has always been a clinical problem. some cases even recur several times a year, and those who recur more than four times a year are diagnosed as recurrent vaginal candidal infection candidiasis, rvvc）。 the common clinical regimen for vvc is to strengthen and consolidate clotrimazole vaginal tablets for up to 25 weeks. however, long-term antibiotic treatment will lead to the decrease of vaginal microflora and the disappearance of inflammation and pathogenic bacteria, which will greatly increase the probability of repeated infection and become a barrier to clinical treatment. if probiotics are added in the treatment, the abundance of lactobacillus can be ensured while antibiotic treatment is carried out, the homeostasis of reproductive tract flora can be reestablished, the defense mechanism can be improved fundamentally, and the re invasion of pathogenic bacteria can be reduced, which will become a new treatment idea and method for radical cure of refractory rvvc. we hypothesize that clotrimazole vaginal tablets with oral lactobacillus is better than clotrimazole vaginal tablets in preventing the recurrence of vulvovaginalcandidiasis.

Eligibility criteria:
inclusion criteria: * women be at least 18 years of age * have symptoms of vulva irritation and or abnormal discharge * meet the clinical criteria for rvvc * willing to participate in research exclusion criteria: 1. taking / injecting antibiotics in the past two weeks; 2. a woman who intends to be pregnant, pregnant or lactating; 3. long term use of contraceptives and immunosuppressants; 4. postmenopausal; 5. there was no same fixed sexual partner (rsp) before and after treatment 6. patients with severe gastrointestinal diseases, including colorectal cancer, ibs, ibd, chronic or acute diarrhea, long-term constipation, etc., or receiving gastrointestinal surgery and abdominal surgery within one year, such as cholecystectomy; 7. patients with severe heart, liver and kidney dysfunction, mental diseases, infectious diseases, tumors, severe anemia, and severe autoimmune diseases (such as rheumatoid arthritis, lupus erythematosus, etc.)

Keywords: recurrent vulvovaginal candidiasis lactobacillus reproductive tract flora
claricore™ biopsy system in patients undergoing radical retropubic prostatectomy

Conditions: Prostate Cancer

Summary: the purpose of the study is to collect information on prostate tissue biopsies collected with the claricore system during a radical prostatectomy procedure. the claricore system is designed to improve how biopsies are taken from the prostate by using light sensors (fiber optics) that can see changes in the tissue. the information collected from the study will be used to develop a method to tell the difference between normal and suspicious tissue to help guide the physician during a biopsy procedure.

the overall objective of this study is to acquire and analyze spectral data and correlative tissue biopsy cores using the claricore system for the purpose of algorithm development. the system algorithm will be trained to identify real-time in vivo 'normal' versus 'suspicious' prostate tissue. the 'normal' or 'suspicious' assignment will be based on the optical signal principle component parameters of the measured signal when compared to a threshold to be derived from pathologically known values of suspicious (or possibly cancerous) and normal (or non-cancerous) measurements in prostate tissue.

Eligibility criteria:
inclusion criteria: * patient scheduled for radical retropubic prostatectomy * prostate volume \> 20cc and height at least 22mm (at the area(s) to be biopsied) as verified by ultrasound or mri * patient, or authorized representative signs a written informed consent form to participate in the study, prior to any study mandated determinations or procedure exclusion criteria: * patient opted for robotic (da vinci robot) or laparoscopic surgery * any condition, or history of illness or surgery that, in the opinion of the investigator, might confound the results of the study or pose additional risks to the patient (e.g. significant cardiovascular conditions or allergies) * patient has systemic infection or evidence of any surgical site infection (superficial or organ space), including active urinary tract infection * bladder cancer (current or prior) * actively taking blood thinning agents (with the exception of low dose aspirin {81 mg}, plavix, coumadin etc.) or severe medical comorbidity prohibiting halting of anticoagulation therapies or history of bleeding disorder (e.g. coagulopathy) * any malignancy other than non-melanoma cell skin cancer, unless no evidence of disease for a minimum of 5 years * hormone therapy for locally advanced disease (except patients on 5-alpha reductase inhibitors to reduce the size of the prostate) * neo-adjuvant hormonal therapy * salvage radical prostatectomy, i.e., patients having surgery due to failure of previous therapy (radiation, brachytherapy, cryotherapy, etc.) * patient has compromised immune system or autoimmune disease (wbc \ 20,000) * patient is not likely to comply with the follow-up evaluation schedule * patient is participating in a clinical trial of another investigational drug or device * patient is mentally incompetent or a prisoner
evaluation of the efficacy and safety of oxacom® in patients with pulmonary arterial hypertension

Conditions: Pulmonary Arterial Hypertension

Summary: a multicenter, randomized, double-blind, placebo-controlled, phase ii-iii clinical trial to evaluate the efficacy and safety of the study drug in adult patients with pulmonary arterial hypertension (pah). the trial will evaluate the efficacy and safety of both single and multi-dose (seven-day) administrations of the study drug in three dosages: 0.03 mg/kg, 0.10 mg/kg, and 0.17 mg/kg. the trial is an observer-blinded trial, since the appearance of the study drug and placebo differs from each other. patients included in the trial, as well as trial coordinators, investigators, and study center staff will be blinded. the only unblinded staff in the study centers will be those who preparing ip/placebo and administering ip/placebo to the study patients. the trial will include 200 patients with pah, who will be sequentially included in the trial in two stages.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of pah ii or iii functional class according to who classification * symptomatic pah group 1 according to clinical classification * patients who have not previously received any pah-specific therapy or patients who have received endothelin receptor antagonists and/or iloprost/selexipag at stable doses for at least 3 months prior to the initial right heart catheterization. * ability to perform reproducible 6-min walking test at the screening with a distance from 150 to 450 m. exclusion criteria: * as per the study protocol

Keywords: oxaсom pulmonary arterial hypertension new russian drug
clinical diagnosis of teenagers admitted to pediatric departments

Conditions: Anorexia; Thalassemia; Sickle Cell Anemia; Chronic Renal Failure; Suicide Attempt

Summary: this study intends to analyze the clinical characteristics of teenagers admitted to pediatric wards due to organic illness and non organic diagnosis, including patients suffering from chronic diseases and comorbidity.

the intention is to summarize the data from year 2000 to 2007 af all the teenagers aged 14 ys to 20 yes admitted to the pediatric wards at the ha'emek medical center. the demographic and clinical date will be summarized.

Eligibility criteria:
inclusion criteria: all the patients ages 14 to 20 ys admitted to the pediatric ward. exclusion criteria: no exclusion criteria relevant.
effectiveness of virtual reality in hand therapy

Conditions: Distal Radius Fracture; Chronic Regional Pain Syndrome; Flexor Tendon Rupture

Summary: the purpose of this study is to determine if the use of virtual reality as an intervention for patients following specific hand injuries will positively affect patients with decreased hand function and reduce pain and improve outcomes. participants will be recruited from 3 different clinics in central kentucky.

participants will participate in four sessions of therapy treatment over a 2-3 week time span of schedule therapy appointments during their active phase of rehabilitation for approximately 1-hour virtual reality (vr) training dosage which will be recorded. the specific virtual reality games within the oculus quest 2 vr system will be selected by the therapist providing interventions each session. in addition to the virtual reality intervention noted above, participants will participate in a pre and post-test outcome measure session (25-30 minutes) with a research team member. (see outcome measure section for more details).

Eligibility criteria:
inclusion criteria: 1. attending hand therapy for rehabilitation of an upper extremity injury with a diagnosis of distal radius fracture, complex regional pain syndrome or tendon ruptures 2. must be in an active exercise phase of rehabilitation exclusion criteria: 1. not in a phase in their rehabilitation in which they can perform active exercises 2. having arm injury due to a neurological disorder (stroke, multiple sclerosis, spinal cord injury, other) 3. non-english speaking 4. patient reporting a history of severe claustrophobia or motion sickness

Keywords: virtual reality function hand therapy exercises
the effectiveness of telerehabilitation-based exercises in elderly people

Conditions: Telerehabilitation; Elderly People; Social Isolation

Summary: an epidemic of pneumonia , which is thought to have developed due to a new coronavirus, was detected in wuhan, hubei province of the people's republic of china, and this epidemic could not be brought under control, leading to other provinces of china in a short time and then to a pandemic. it has spread all over the world including the european continent. causative acute respiratory syndrome-coronavirus-2 (sars-cov-2) and the disease caused by the new virus (novel) coronavirus-2019 (2019-ncov) and subsequently the covid-19. after the virus was officially detected in our country on 11 march 2020, the number of cases increased rapidly and the virus was isolated in 670 patients within 10 days. the group that is most affected by the outbreak and has the highest mortality rate is the elderly with known cardiovascular diseases. it is important to ensure the social isolation of elderly patients and to minimize all hospital applications as much as possible if they do not have life-threatening urgent problems. to this end, turkey on 21 march 2020, 65 years of age and older people and patients with chronic curfew was implemented. individuals moving away from social life are dealing with their body more, their level of depression and anxiety increase, and their physical functions decrease. the therapy service is offered to people who cannot travel with telerehabilitation, which is defined as the transmission of rehabilitation service to long distances by using electronic information and communication technology. the purpose of this study is to investigate the effects of telerehabilitation exercises given to elderly individuals on sleep quality, quality of life and balance within the scope of geriatric rehabilitation.


Eligibility criteria:
inclusion criteria: * individuals aged 65 and over,mini mental status scale 24 and above, to be able to communicate verbally and visually,those who do not have serious heart disease (aortic stenosis, angina, hypertrophic cardiac myopathy, arrhythmia, pacemaker) that may prevent exercise,having the necessary technological competence to provide remote video communication at home,to be at least 20 m ambassador exclusion criteria: * mini mental status scale being lower than 24,those with serious heart disease (aortic stenosis, angina, hypertrophic cardiac myopathy, arrhythmia, pacemaker) that may interfere with exercise,visual or auditory loss

Keywords: covid-19 exercise
the effect of damask rose essential oil aromatherapy on dental anxiety and pain on children

Conditions: Dental Anxiety

Summary: this study aims to evaluate and compare the role of damask rose essential oils in reducing a child's dental anxiety and pain undergoing local anesthesia administration

dental anxiety is recognized as one of the major public health problems. it can lead to avoidance of necessary dental care, which affects oral health negatively, especially in children where dental care providers face a challenge to control dental anxiety to manage the child in the dental visit. overall prevalence of dental anxiety was 23.9% with less prevalent in adolescents (13.3%), more prevalent in preschoolers (36.5%), and schoolchildren (25.8%). methods for managing anxiety in dentistry are both pharmacological and non-pharmacological. aromatherapy is one of the non-pharmacological methods, it is a simple, inexpensive, non-invasive method introduced by the use of aromatic essential oils through the sense of smell to produce positive physiological effects, relaxation and relieve anxiety symptoms. aromatherapy can also decrease pain perception during local anesthetic injections in children. rosa damascene is commonly known as damask roses, a plant belonging to the rosaceae family. the flowers of this plant are large, showy and colorful. for its scent, it is also used in the production of essential oil and rose water. the r. damascena plant has also been used for medicinal applications it has analgesic, anti-inflammatory, anti-headache, and muscle-relaxing effects, and due to its strong depressing effect on the central nervous system it has hypnotic, anticonvulsant, antidepressant, and ant anxiety, effects. the effect of rose oil in reducing pain has been conducted in children who are hospitalized for surgery, measuring the effect on post-operative pain intensity. also, the effect of rose oil in the reduction of dental anxiety has already been studied but has been conducted on adults orthodontic patients.

Eligibility criteria:
inclusion criteria: * egyptian children from 7 to 12 years old require local anesthesia administration. * absence of any systemic problems, physical and mental disabilities. * children intellectually sufficient to complete the anxiety scale and those whose parents were willing to participate in the study. * frankel rating 3 in cooperation exclusion criteria: * presence of dental or medical emergency and systemic disorders. * special needs children. * children with any respiratory tract illnesses, common, cold or allergy.

Keywords: aromatherapy
phase ii anetumab ravtansine as 2nd line treatment for malignant pleural mesothelioma (mpm)

Conditions: Mesothelioma

Summary: the main purpose of the 15743 study is to assess efficacy and safety of anetumab ravtansine versus vinorelbine in progression free survival in patients with stage iv mesothelin overexpressing malignant pleural mesothelioma (mpm). 210 eligible patients will be randomized to receive either anetumab ravtansine every three weeks or weekly vinorelbine. treatment will continue until centrally confirmed disease progression or until another criterion is met for withdrawal from the study. patients will enter follow up phase to capture safety and endpoint data as required. efficacy will be measured by evaluating progression free survival from randomization. radiological tumor assessments will be performed at defined time points until the patient's disease progresses. blood samples will be collected for safety, pharmacokinetic and biomarker analysis. archival or fresh biopsy tissue may also be collected for central pathology review and biomarkers.


Eligibility criteria:
inclusion criteria: * histological documentation of malignant pleural mesothelioma (mpm) overexpressing mesothelin * unresectable locally advanced or metastatic mpm after locally confirmed progression on 1st line treatment with platinum in combination with pemetrexed. * patients must have measurable disease * eastern cooperative oncology group performance status (ecog ps) of 0 or 1 * life expectancy of at least 3 months. * adequate bone marrow, liver and renal function * left ventricular ejection fraction (lvef) ≥ 50% or the lower limit of normal (lln) according to local institution ranges of normality. exclusion criteria: * more than 1 previous systemic anti-cancer therapy line * patients with corneal epitheliopathy or any eye disorder that may predispose the patients to this condition at the discretion of the investigator in consultation with the ophthalmologist. * brain metastases, meningeal tumours or other metastases in the central nervous system * evidence of history of bleeding diathesis. * ongoing or active infection (bacterial, fungal, or viral) of national cancer institute's common terminology criteria for adverse events (nci-ctcae) version 4.03 grade \> 2. * pre-existing cardiac conditions
brentuximab for newly diagnosed hodgkin disease

Conditions: Hodgkin Lymphoma

Summary: the addition of brentuximab vedotin (bv) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed hodgkin lymphoma (hl).


Eligibility criteria:
inclusion criteria: * normal serum creatinine based on age or creatinine clearance \>60 ml/min/1.73 m2 or an equivalent radioisotope glomerular filtration rate (gfr) as determined by the institutional normal range. * direct bilirubin \< 1.5 upper limit of normal (uln) for age, and sgot (ast) or sgpt (alt) \<3 x uln * shortening fraction \>27% by echocardiogram, or * ejection fraction of \>50% by radionuclide angiogram or echocardiogram. * for patients age 1-16 years, lansky score of ≥60. * for patients \> 16 years, karnofsky score of ≥60. * no prior hodgkin lymphoma directed therapy is allowed except for emergent mediastinal irradiation (\<1000cgy) for superior vena cava (svc) syndrome. exclusion criteria: * females who are pregnant (positive hcg) or lactating. * karnofsky \<60% or lansky \<60% if less than 16 years of age. * age ≤1 year or \>29.99 years of age.